| Dataset | DGIdb Drug Targets 2026 |
| Category | physical interactions |
| Type | drug |
| Description | A monocarboxylic acid that is 1,3-thiazolidine which is substituted on the nitrogen by a carboxymethyl group, at positions 2 and 4 by thioxo and oxo groups, respectively, and at position 5 by a 2-methyl-3-phenylprop-2-en-1-ylidene group. It is an inhibitor of aldose reductase (which catalyses the conversion of glucose to sorbitol) and is used for the treatment of some diabetic complications, including neuropathy. (Chemical Entities of Biological Interest Ontology, CHEBI_31539) |
| External Link | https://dgidb.org/results?searchType=drug&searchTerms=EPALRESTAT |
| Similar Terms | |
| Downloads & Tools |
5 interacting proteins for the EPALRESTAT drug from theDGIdb Drug Targets 2026 dataset.
| Symbol | Name | Standardized Value |
|---|---|---|
| CYP4A11 | cytochrome P450, family 4, subfamily A, polypeptide 11 | 3.5288 |
| AKR1B1 | aldo-keto reductase family 1, member B1 (aldose reductase) | 1.11436 |
| SLC5A7 | solute carrier family 5 (sodium/choline cotransporter), member 7 | 0.341497 |
| MAPT | microtubule-associated protein tau | 0.0238432 |
| VDR | vitamin D (1,25- dihydroxyvitamin D3) receptor | 0.0216934 |